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Key Points
• TA-316, a novel CMA,
enhances human plate-
let ex vivo generation
from iPS cells.
• TA-316 exhibited bi-
ased megakaryopoiesis
at levels comparable to
rhTPO and superior to
eltrombopag.
Signaling by thrombopoietin (TPO) in complex with its receptor, c-MPL, is critical for
hematopoietic stem cell (HSC) homeostasis and platelet generation. Here we show that
TA-316, a novel chemically synthesized c-MPL agonist (CMA), is useful for ex vivo platelet
generation from human-induced pluripotent stem (iPS) cell–derived immortalized
megakaryocyte progenitor cell lines (imMKCLs). Moreover, the generation is clinically
applicable, because self-renewal expansion and platelet release is tightly controllable.
TA-316 but not eltrombopag, another CMA, promoted both the self-renewal and maturation
of imMKCLs, leading to more than a twofold higher platelet production than that achieved
with recombinant human TPO (rhTPO). Interestingly, TA-316 seemed to favor MK-biased
differentiation from bone marrow CD341 HSC/progenitors and imMKCLs through the
upregulation of vascular endothelial growth factor A and ﬁbroblast growth factor 2. This
result suggests TA-316 could facilitate the development of an eﬃcient and useful system to
expand platelets from imMKCLs.
Introduction
Platelet transfusion plays a pivotal role in the management of patients with bleeding due to a severe
decrease in platelet production or platelet dysfunction. However, platelets can be obtained only through
blood donation, which represents an unstable supply of platelets for clinical use.1,2 Moreover, repeated
transfusion leads to the induction of antibodies against allogeneic HLA and/or human platelet antigens
on the donor-derived platelets, necessitating the use of identical HLA/human platelet antigens-matched
platelets.3 To overcome these issues, there have been various attempts to expand human platelets ex
vivo.4 It has been anticipated, for example, that the eventual use of human-induced pluripotent stem
cells (hiPSCs) as a robust source of platelets would obviate or relieve the problem of allo-immunization.5
In that context, we established an in vitro iPS-Sac culture system for differentiation into megakaryocytes
(MKs, platelet precursors),5,6 which also yields T lymphocytes.7 Unfortunately, the efficiency of the MK
production is extremely low.5 We therefore established self-renewing immortalized MK progenitor cell
lines (imMKCLs) from hiPSCs as a starting material of platelet supply, because they exhibit a capacity for
the long-term expansion of MKs that produce a substantial yield of platelets.8
Thrombopoietin (TPO) is the primary regulator controlling human MK differentiation and platelet
production, as well as the expansion of platelets from imMKCLs. However, TPO has failed as a standard
therapy due to immunogenicity that worsens thrombocytopenia.8-10 Instead, several nonpeptidyl small
molecules that activate c-MPL, the TPO receptor, have recently been developed.11,12 These include
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eltrombopag, an orally administered drug used to treat mostly
immune-thrombocytopenia. The advantages of such chemically
synthesized c-MPL agonists (CMAs) over peptide-based ligands
include greater biological safety, lower immunogenicity, and lower
manufacturing costs. Detailed examination of the activities of CMAs
also promotes a better understanding of the signaling pathways that
regulate megakaryopoiesis and thrombopoiesis. Considering that
some CMAs activate signals that are preferentially specialized for
platelet differentiation, we evaluated their effects on the expansion
capacity of imMKCLs. This effort led us to identify TA-316 as a
compound that increases platelet production from imMKCLs more
efficiently and cost effectively than TPO or eltrombopag. Our results
provide promising possibilities for the use of small-molecule com-
pounds in the realization of regenerative medicine using hiPSCs.
Methods
Cell culture
Bone marrow (BM) CD341 cells. Human BM CD341 cells were
purchased from Lonza (Basel, Switzerland). Cells were suspended in
StemSpan (Stemcell Technologies, Vancouver, BC, Canada) supplemented
with 100 ng/mL recombinant human stem cell factor (rhSCF) (R&D
Systems, Minneapolis, MN) and seeded onto 48-well plates (20 000 cells/
500 mL per well). Thereafter, recombinant human TPO (rhTPO) (PeproTech,
Rocky Hill, NJ), TA-316 (in-house synthesized), eltrombopag (ChemScene,
Monmouth Junction, NJ, or synthesized in-house), or dimethyl sulfoxide
(DMSO) (Wako Pure Chemical Industries [WAKO], Osaka, Japan) was
added to the cell culture for 10 days in a humidified incubator at 37°C with
5% CO2. We confirmed no significant differences in the purities and
proliferation of cells treated with purchased (ChemScene) and in-house
synthesized eltrombopag (data not shown). In-house synthesized eltrombo-
pag was used for all experiments unless otherwise noted.
C3H10T1/2 cells. Mouse C3H10T1/2 cells (RIKEN BioResource
Center, Ibaraki, Japan) weremaintained in Basal Medium Eagle (Thermo Fisher
Scientific, Waltham, MA) containing 10% fetal bovine serum (FBS) (Thermo
Fisher Scientific). Cells were cultured in a humidified incubator at 37°C with
5% CO2.
hiPSC-derived induced hematopoietic progenitor cells (iHPCs).
hiPSCs (clone; Tkda3-4) were maintained in Dulbecco’s modified Eagle
medium /Ham’s F12 medium (WAKO) containing 20% StemSure Serum
Replacement (WAKO), 1% minimal non-essential amino acids solution
(Thermo Fisher Scientific), 1% StemSure (WAKO), 50 mM monothiogly-
cerol solution (3100) (WAKO), 292 mg/mL L-glutamine (Thermo Fisher
Scientific), 100 U/mL penicillin (Thermo Fisher Scientific), and 100 mg/mL
streptomycin (Thermo Fisher Scientific). Colonies were removed from the
dish using dissociation solution for human embryonic stem/iPS cells
(ReproCELL, Kanagawa, Japan) and seeded onto 0.1% gelatin-coated
plates or dishes, along with mitomycin C (WAKO) treated (10 mg/mL, 1.5 to
2 hours) C3H10T1/2 cells (200 000 cells per well in 6-well plates or 800
000 cells per 100-mm dish). The plated cells were cultured in endothelial
basal medium (EBM) (Iscove modified Dulbecco medium [Sigma-Aldrich,
St Louis, MO]), supplemented with 15% FBS (Thermo Fisher Scientific),
292 mg/mL L-glutamine (Thermo Fisher Scientific), 100 U/mL penicillin (Thermo
Fisher Scientific), 100 mg/mL streptomycin (Thermo Fisher Scientific),
0.05 mg/mL ascorbic acid (Sigma-Aldrich), 0.45 mM 1-thioglycerol (Sigma-
Aldrich), and 1% insulin-transferrin-selenium supplement (Thermo Fisher
Scientific), in the presence of 20 ng/mL recombinant human vascular
endothelial growth factor (VEGF)-A165 (WAKO), 5 ng/mL recombinant
human basic fibroblast growth factor (FGF) (ReproCELL), and 10 mM
rock inhibitor (Y-27632, WAKO). The medium was changed every 2 to
4 days. hiPSCs were cultured for 14 days in a humidified incubator (37°C,
5% CO2) and formed sac-like structures (iPS-Sacs) containing iHPCs
inside. Crude iHPCs were collected from iPS-Sacs on day 14 and
further sorted using FACSAria III (BD Biosciences, San Jose, CA) into a
CD341/CD431/CD412/glycophorin-A (GPA2) fraction. Sorted iHPCs and
unsorted iHPCs were seeded onto mitomycin C-treated C3H10T1/2 cells
and cultured for 3 to 10 days in EBM medium supplemented with 50 ng/mL
rhSCF (R&D Systems) and one of 100 ng/mL rhTPO, 100 ng/mL TA-316,
3000 ng/mL eltrombopag, or 0.05% DMSO.
imMKCLs. imMKCL clone 7 was established from hiPSCs as previously
reported.8 imMKCLs bear 3 doxycycline (DOX)-inducible transgenes, c-MYC,
BMI1, and BCL-XL. As such, the addition of DOX turns on the expression of
these transgenes (genes on), leading to proliferation of imMKCLs, whereas the
depletion of DOX (genes off) induces their maturation. imMKCL clone 7
(which we named imMKCL Sev2) was cultured in EBM medium supple-
mented with rhSCF (R&D Systems) and 1 mg/mL DOX (TAKARA, Shiga,
Japan) in the presence of rhTPO (PeproTech), eltrombopag (ChemScene),
TA-316, or DMSO (vehicle). Cells were seeded onto 0.1% gelatin-coated
6-well plates (100 000 cells/mL, 2 mL per well) along with mitomycin
C-treated C3H10T1/2 cells, and cultured in a humidified incubator at 37°C
and 5% CO2, and passaged every 3 to 4 days.
UT-7/TPO cells and UT-7/erythropoietin (EPO) cells. UT-7/TPO and
UT-7/EPO cells were obtained from N. Komatsu (Juntendo University,
Tokyo, Japan),13-15 and cultured in Iscove modified Dulbecco medium
containing 10% FBS in the presence of 10 ng/mL rhTPO and 0.5 U/mL
recombinant human EPO (rhEPO) (Eposin; Chugai Pharmaceutical,
Tokyo, Japan), respectively. Cells were cultured in a humidified incubator
at 37°C and 5% CO2.
Ba/F3 cells. Murine pro–B-cell line Ba/F3 was obtained from RIKEN
Cell Bank (Tsukuba, Japan). Stable transfectants such as Ba/F3-HuMpl
and Ba/F3-MuMpl were established to transfect human or murine c-mpl.16
Ba/F3 cells and their transfectants were maintained in RPMI 1640
medium supplemented with 10% FBS and 10 ng/mL recombinant mouse
interleukin-3 (rmIL-3) or 30 to 50 ng/mL rhTPO.
Cell growth assay
UT-7/TPO, UT-7/EPO, Ba/F3, Ba/F3-HuMpl, and Ba/F3-MuMpl cells
were seeded onto 96-well plates (5000 cells/100 mL per well) and
cultured for 4 days as described earlier in medium supplemented with






























Figure 1. Structures of TA-316 and eltrombopag (olamine).
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at 37°C and 5% CO2. Cell viability was assessed using WST-8 assays
(Cell Counting Kit-8; Dojindo Laboratories, Kumamoto, Japan). A one-
tenth volume of WST-8 solution (10 mL) was added to the cell culture
and incubated for 3 to 4 hours in a humidified incubator at 37°C and
5% CO2. The absorbance at 450 nm was measured using an absorbance
spectrometer (SpectraMax 190; Molecular Devices, Sunnyvale, CA), and
the number of viable cells was measured after subtracting the absorbance of
the medium alone.
Real-time quantitative reverse transcription polymerase chain
reaction (RT-PCR)
RNA was extracted using RNeasy Mini Kits (Qiagen, Valencia, CA)
according to the manufacturer’s instructions, after which complementary
DNAs were synthesized using PrimeScript RT Master Mix (Perfect Real
Time; TAKARA). RT-PCR was carried out for 40 to 50 cycles of 1 minute at
60°C and 15 seconds at 95°C in an ABI PRISM 7700 Sequence Detector
(Applied Biosystems, Foster City, CA). All Taqman primers and probes were
obtained from Applied Biosystems: glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; Hs02758991_g1); GATA binding protein 1 (GATA1;
Hs01085823_m1); zinc finger protein, FOG family member 1 (ZFPM1;
Hs00542350_m1); nuclear factor, erythroid 2 (NFE2; Hs00232351_m1);
Fli-1 proto-oncogene ETS transcription factor (FLI1; Hs00956711_m1);
von Willebrand factor (VWF; Hs04397751_m1); VEGF A (VEGFA;
Hs00173626_m1); and basic FGF2 (Hs00266645_m1). GAPDH served
as an internal control.
Megakaryopoiesis/thrombopoiesis of imMKCLs
imMKCLs were cultured in EBM medium supplemented with rhSCF and
1 mg/mL DOX in the presence of rhTPO, eltrombopag, TA-316, or
DMSO (vehicle). Cells were seeded onto 0.1% gelatin-coated 6-well plates
(100 000 cells/mL, 2 mL per well) along with mitomycin C-treated C3H10T1/2
cells, and cultured in a humidified incubator at 37°C and 5% CO2 and
passaged every 3 to 4 days. Cell proliferation was assessed based on 0.4%
Trypan blue staining (Thermo Fisher Scientific), and the cumulative number
of cells was calculated until day 11. To induce platelet production, c-MYC,
BMI1, and BCL-XL genes were turned off by culturing the imMKCLs in
DOX-free medium. After 4 days of culture, platelets and MKs were gently
collected with their medium by pipetting, and acid citrate dextrose solution
(85 mM trisodium citrate [WAKO], 104 mM D-glucose [WAKO], and 65 mM
citric acid [WAKO]) was added to each sample (10% [volume-to-volume
ratio] final concentration). MKs were centrifuged for 8 minutes at 440 g, after
which the pellets were suspended in phosphate-buffered saline (PBS)
containing 2% FBS.
Flow cytometry
Samples were analyzed on a FACSAria III using FACSDiva software
(BD Biosciences). To analyze megakaryocytic differentiation and matu-
ration, cultured BM CD341 cells, iHPCs, and imMKCLs were col-
lected and stained with antibodies as follows, and added to samples
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Figure 2. TPO receptor-dependent cell proliferation and STAT5 phosphorylation. (A) UT-7/TPO and (B) UT-7/EPO cells were cultured for 4 days with various doses
of rhTPO, TA-316, eltrombopag, or rhEPO, and the number of cells were counted using the WST-8 assay. (C) Ba/F3 cells, Ba/F3 cells with human c-MPL (Ba/F3-HuMpl), and
Ba/F3 cells with murine c-MPL (Ba/F3-MuMpl) were similarly cultured and counted after 4 days with rmIL-3 (1 ng/mL), rhTPO (100 ng/mL), TA-316 (1 ng/mL), or eltrombopag
(ChemScene; 100 ng/mL). (D) Ba/F3-HuMpl cells were similarly cultured and counted after 4 days with various doses of rhTPO, TA-316, or eltrombopag (ChemScene). (E)
STAT5 phosphorylation in UT-7/TPO cells stimulated for 15 to 360 minutes with rhTPO (100 ng/mL), TA-316 (100 ng/mL), eltrombopag (ChemScene; 1000 ng/mL), or DMSO
(vehicle) were evaluated using BD Phosflow (STAT5, pY694).4MFI values of pSTAT5 are shown as relative values to that of vehicle treatment. Data represent the mean and SD;
*P , .05, †P , .05. MFI, mean fluorescence intensity; min, minutes; O.D., optical density; pSTAT5, phosphorylated STAT5.
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(PE)-conjugated anti-human CD34 (BD Biosciences), allophycocyanin
(APC)-conjugated anti-human CD41 (BioLegend, San Diego, CA),
Pacific blue-conjugated anti-human CD41 (Affymetrix, San Diego, CA),
PE-conjugated anti-human CD42b (Affymetrix), APC-conjugated anti-
human CD43 (Affymetrix), and APC-conjugated CD235a (GPA; BD
Biosciences). To evaluate the number of multinucleate MKs, Hoechst
33342 (Thermo Fisher Scientific) was added to part of each sample
(20 mg/mL final concentration), and the samples were incubated for
45 minutes in a water bath at 37°C and then washed with cold 2% FBS/
PBS. All samples were then incubated for 30 minutes on ice in the dark.
After washing with 2% FBS/PBS, cells were centrifuged for 5 minutes at
1500 rpm and resuspended with 2% FBS/PBS. Dead cells were excluded
based on propidium iodide (Biomol, Hamburg, Germany) staining at a final
concentration of 1 mg/mL.
Platelet production from imMKCLs
imMKCL-derived platelets were collected as described earlier. Total
platelet numbers were determined using BD TruCount tubes (BD
Biosciences), in combination with APC-conjugated anti-human CD41
(BioLegend) and PE-conjugated anti-human CD42b (Affymetrix) anti-
bodies. Cells were stained for 15 minutes at room temperature and
analyzed using fluorescence-activated cell sorting (FACS).
First procaspase activating compound (PAC-1) binding assay
The procedures used were described previously.8
Intracellular phospho-specific flow cytometry
The phosphorylation of signaling proteins in UT-7/TPO cells and imMKCLs
was evaluated using the BD Phosflow assay (BD Biosciences). Before the
tests, imMKCLs were cultured for 24 hours without rhTPO. UT-7/TPO cells
and imMKCLs were then collected, washed twice with PBS, and
resuspended in TPO-free culture medium (1 000 000 cells/500 mL per
sample). Each sample was pre-incubated in a humidified incubator at 37°C
and 5% CO2 for 30 minutes and stimulated with rhTPO, TA-316,
eltrombopag, or DMSO for 15 to 240 minutes. During the last 30 minutes,
APC-conjugated anti-human CD41a (BioLegend) antibody was added to
the cells. For the 15-minute stimulation samples, antibodies were added at
the same time as the TPO receptor agonists. Stimulated cells were fixed
immediately using the same volume of pre-warmed BD Cytofix (BD
Biosciences) (37°C, 10 minutes) and centrifuged at 600 g for 6 minutes.
The pellets were resuspended in 1 mL of cooled Perm Buffer III (BD
Biosciences) and incubated on ice for 30 minutes. After permeabilization,
the cells were washed 3 times with 3 mL of 2% FBS/PBS (centrifuged at
600 g for 6 minutes) and stained with antibodies (PE-conjugated anti-STAT5
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Figure 3. TA-316 induces megakaryopoietic differentiation fromBMCD341 cells. BMCD341 cells were cultured for 10 days with rhTPO (50 ng/mL), TA-316 (800 ng/mL),
eltrombopag (3000 ng/mL), or DMSO (0.05%). The CD411 cell population was analyzed using FACS (A), and the expressions of GATA1, ZFPM1, FLI1, NFE2, and VWF
mRNA were evaluated using RT-PCR (B). GAPDH served as an internal control. Data represent the mean and SD; *P , .05, **P , .01. mRNA, messenger RNA.
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anti-STAT1 [pY701], PE-conjugated anti-AKT [pS473], Alexa 488-conjugated
anti-extracellular signal-regulated kinase 1/2 [pT202/pY204], and/or corre-
sponding isotype controls; BD Biosciences) for 60 minutes at room
temperature in the dark. The cells were then washed with 3 mL of 2% FBS/
PBS, centrifuged at 600 g for 6 minutes, resuspended in 200 mL of 2%
FBS/PBS, and analyzed by FACS. Signals were normalized to no-agonist
(Vehicle, DMSO alone) samples.
Statistical analysis
All results are presented as the mean 6 standard deviation (SD). Statistical
significance was analyzed using the Dunnett test. The level of significance
was set at 0.05.
Results
Identification of TA-316 as a novel chemically
synthesized CMA
We first assessed the abilities of CMAs synthesized in-house to
promote the proliferation of UT-7/TPO cells, a human leukemia cell
line that expresses c-MPL, and selected the most potent candidate,
TA-316 (Figure 1) (data not shown). These effects by TA-316
were dependent on c-MPL, as evidenced by TA-316 enhancing
the growth of UT-7/TPO (Figure 2A) and Ba/F3 cells with c-MPL
(Ba/F3-HuMpl) (Figure 2C-D), but not UT-7/EPO (Figure 2B), Ba/
F3 without human c-MPL (Ba/F3), or Ba/F3 with murine c-MPL (Ba/
F3-MuMpl) cells (Figure 2C). The median effective concentrations
(ie, EC50) of TA-316, rhTPO, and eltrombopagwere 0.360.03 ng/mL,
1.6 6 0.17 ng/mL, and 55.3 6 5.04 ng/mL, respectively, in assays
using UT-7/TPO cells (Figure 2A), and 0.65 6 0.23 ng/mL, 11.7 6
0.74 ng/mL, and 20.7 6 2.0 ng/mL, respectively, in assays using
Ba/F3-HuMpl cells (Figure 2D). We confirmed TA-316 stimulated
UT-7/TPO and Ba/F3-HuMpl cell proliferation more strongly than
either rhTPO or eltrombopag (Figure 2A,D). Intracellular phospho-
protein analysis revealed that TA-316 induced sustained STAT5
phosphorylation (Figure 2E), which is likely to have elicited the more
potent effect by TA-316.
TA-316 promotes biased megakaryopoiesis and
upregulated MK lineage markers
We then examined the effect of TA-316 on BM CD341 cell
differentiation and observed that TA-316 increased the number of
CD411 MK lineage cells after 10 days of culture (Figure 3A) with
continued enhancement of STAT5 activation in UT-7/TPO cells
(data not shown and Figure 2E). Interestingly, TA-316 also
upregulated the gene expression of 5 specific markers of the MK
lineage (GATA1, ZFPM1, FLI1, NFE2, and VWF) in cultured BM
CD341 cells to a greater degree than rhTPO, whereas eltrombopag
did not show this effect (Figure 3B).
TA-316 expands MKs from hiPSC-derived iHPCs ex
vivo more efficiently than eltrombopag
We next prepared iHPCs using our iPS-Sac system5 and tested
whether TA-316 affects MK production. We found that at 100 ng/mL,
TA-316 increased MK numbers more efficiently than rhTPO
and eltrombopag (supplemental Figure 1A). TA-316 also tends
to promote multinuclearity and increase ploidy (supplemental
Figure 1B). When the CD431CD341CD412GPA2 population
was sorted from crude iHPCs using flow cytometry and cul-
tured for another 5 days in the presence of rhTPO, TA-316, or
eltrombopag, TA-316 and rhTPO increased the number of
CD411 MKs best (Figure 4). Collectively, the results summa-
rized to this point indicate that TA-316 is a specific CMA with a
greater ability to stimulate biased and efficient human megakar-
yopoiesis ex vivo that is comparable with rhTPO and superior to
eltrombopag.
TA-316 expands MKs and platelets from imMKCLs ex
vivo more efficiently than TPO or eltrombopag
We next cultured imMKCLs for 11 days in the presence of rhTPO,
TA-316, or eltrombopag to reach the self-renewal stage, and then
for an additional 4 days to reach the platelet production stage
(Figure 5A). On day 11, the total number of cells obtained in culture
with 200 ng/mL TA-316 was 1.5-fold to greater than twofold higher
than in cultures with 50 ng/mL rhTPO and even 3000 ng/mL
eltrombopag, respectively (Figure 5B). When we turned off c-MYC,
BMI1, and BCL-XL expression to induce platelet production,
TA-316 increased the number of CD411CD42b1 platelets by
more than twice that of rhTPO (P , .001), whereas eltrombopag
had little effect on platelet production (Figure 5C). The relative
number of CD411CD42b1 platelets produced per single imMKCL
cell treated with TA-316 was 1.3-fold higher than that with rhTPO.
We attributed this higher platelet yield by TA-316 treatment to the
A
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Figure 4. TA-316 induces megakaryopoietic differentiation from iPS-Sac–
derived hematopoietic progenitor cells. (A) Scheme of megakaryopoiesis and
thrombopoiesis in iPS-Sac–derived iHPCs. hiPSCs cultured for 14 days with VEGF-
formed sac-like structures (iPS-Sacs). CD431/CD341/CD412/GPA2 iHPCs were
sorted from crude iHPCs in iPSC-Sacs using FACS and then cultured with rhTPO
(100 ng/mL), TA-316 (100 ng/mL), or eltrombopag (3000 ng/mL). (B) The number of
CD411 cells was evaluated using FACS on days 3 and 5. Data represent the mean and
SD; **P , .01, ***P , .001. n.s., not significant.
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combination of enhanced imMKCL expansion and platelet yield
per cell. In addition, imMKCLs stimulated with TA-316 or rhTPO
showed high levels of DNA content (Figure 6A; supplemental
Figure 2). The level of binding to PAC-1 on platelets by thrombin
stimulation, which is a key parameter of aIIbb3 integrin-dependent
platelet functionality, was the same in platelets generated using
TA-316 or rhTPO (Figure 6B). An electron microscope image of
platelets obtained under the TA-316 condition showed normal
platelet structures (supplemental Figure 3). These results indicate
that TA-316 enhanced the production of imMKCL-derived platelets
and that the platelets showed a competency comparable to those
produced with rhTPO.
We also observed that TA-316 persistently activated STAT5 in
imMKCLs (supplemental Figure 4A) as it did in UT-7/TPO cells
(Figure 2E). Further analysis revealed that TA-316 induced the
phosphorylation of components in 3 major TPO signaling pathways:
JAK/STAT, MAPK, and phosphatidylinositol 3-kinase/AKT, within
imMKCLs (supplemental Figures 4B-E and 5). These results
indicate that TA-316 acts on imMKCL as a TPO receptor agonist,
and enhances imMKCL expansion and platelet production.
TA-316 preferentially enhances VEGFA and
FGF2 expression
Consistent with the data of BM CD341 cells shown in Figure 3B,
GATA1, ZFPM1, FLI1, NFE2, and VWF were upregulated in
imMKCLs at the platelet production stage to a greater degree
with TA-316 than with rhTPO (Figure 6C), whereas eltrombopag
showed little capacity to enhance the expression of these
thrombopoiesis-specific genes in imMKCLs. To determine
the molecular mechanisms underlying the beneficial actions of
TA-316 on platelet production from imMKCLs, we performed DNA
microarray-mediated transcriptional profiling of imMKCLs cultured
with TA-316 and found greater upregulation of growth factor
activity-related genes, including VEGFA and FGF2, than that seen
with rhTPO (supplemental Table 1). Real-time quantitative PCR
confirmed the superior effect of TA-316 on the induction of these
genes in imMKCLs (Figure 7A). Moreover, earlier observations that
VEGFA and FGF2 are involved in the MK maturation associated
with thrombopoiesis17,18 suggest the greater efficacy of TA-316
may reflect VEGFA and FGF2 upregulation. This hypothesis was
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Figure 5. TA-316 promotes megakaryopoiesis and
thrombopoiesis in imMKCLs. (A) System to generate platelets
from imMKCLs cultured with rhTPO, TA-316, eltrombopag, or
DMSO (vehicle). Cells were seeded onto mitomycin C-treated
C3H10T1/2 feeder cells and passaged every 3 to 4 days. To turn
off the c-MYC, BMI1, and BCL-XL genes in order to induce platelet
production, beginning on day 11, the cells were cultured in DOX-
free medium. After 4 days of culture, matured MKs and platelets
were collected. (B) The number of imMKCLs was counted on day
11 based on Trypan blue assays. (C) On day 15, imMKCL-derived
platelets were collected, and CD411/CD42b1 platelets were
counted using FACS. Data represent the mean and SD; **P, .01,
***P , .001.
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antagonist, axitinib (5 nM) or an anti-FGF receptor antagonist,
PD173074 (100 nM). These drugs reversed the cell proliferation of
imMKCLs in the presence of TA-316, whereas epithelial growth
factor receptor antagonist, gefitinib, did not (Figure 7B). Neither
axitinib nor PD173074 showed an effect on platelet production or
the expression of differentiation markers (CD41 and CD42b) in
imMKCLs (data not shown).
Discussion
A stable supply for platelet transfusion by hiPSC technology needs
an efficient and robust cell culture system that generates large
quantities of platelets at low cost. To address this issue, we have
developed stable imMKCLs from hiPSCs, which enable the long-
term expansion of MKs and efficient production of platelets.8 In the
present study, we focused particularly on TPO/c-MPL signaling,
which plays a primary role in megakaryopoiesis and thrombopoiesis,
and identified TA-316 as a novel small-molecule CMA that
promotes the proliferation and differentiation of human c-MPL–
expressing cells. Indeed, in proliferation assays using UT-7/TPO
cells and Ba/F3-HuMpl cells, TA-316 showed an EC50 of 0.3 ng/mL
and 0.65 ng/mL, values superior to either rhTPO (1.6 ng/mL and
11.7 ng/mL) or another CMA, eltrombopag (55.3 ng/mL and
20.7 ng/mL) (Figure 2A,D). Of the 3 CMAs examined, TA-316 was
most potent for the proliferation of UT-7/TPO cells, Ba/F3-HuMpl
cells, and imMKCLs (Figure 5B). In differentiation settings using BM
CD341 cells and human iPSCs, TA-316 had a comparable effect to
rhTPO and a more potent one than eltrombopag (Figures 3A and
4B). Interestingly, TA-316 seemed to be also most potent for the
terminal maturation of MKs from human hiPSCs (supplemental
Figure 1A) and platelet yield from imMKCLs (Figure 5C).
In addition to the fact that both TA-316 and eltrombopag showed
no effect on mouse c-mpl (Figure 2C) and showed later activation
patterns (Figure 2E; supplemental Figures 4A and 5), TA-316
and eltrombopag share chemical structures (Figure 1). Another
chemical, NIP-004, from which TA-316 was derived, also has no
effect on mouse c-mpl.16 Therefore, despite the different potencies,
these compounds may function similarly at the molecular level, but
in a way is distinct from TPO.
We also demonstrated that TA-316 prevails over TPO and
eltrombopag in the ex vivo production of platelets from hiPSCs,
as evidenced by the final platelet yield for which TA-316 induced
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*p<0.05, **p<0.01, vs. TPO (Genes Off)
Figure 6. TA-316 induces maturation of imMKCLs and increases
functional platelets. imMKCLs cultured with rhTPO (50 ng/mL),
TA-316 (200 ng/mL), eltrombopag (1000 ng/mL), or DMSO (0.05%)
were collected on day 11 (genes on) and day 15 (after 4 days without
DOX, genes off). (A) Multinucleated ($8 n) MKs and (B) PAC-1 binding
on platelets were analyzed by FACS. Platelets were stimulated for
15 minutes with 1 U/mL thrombin from human plasma. Human washed
platelets served as a positive control. (C) mRNA expressions ofGATA1,
ZFPM1 (FOG1), NFE2, FLI1, and VWF (genes on or off) were
evaluated using Taqman PCR assays. GAPDH served as an internal
control. Data represent the mean and SD; *P , .05, **P , .01. PLT,
platelets.
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eltrombopag (Figure 5C). These findings suggest that the combi-
nation of TA-316 with imMKCLs is applicable to a culture system
for the clinical supply of hiPSC-derived platelets.8
To further investigate the effect of TA-316 on the platelet differen-
tiation of c-MPL–expressing cells, we analyzed the gene expression
of specific markers of MK lineage in culture with rhTPO, eltrombopag,
or TA-316. TA-316 tended to enhance the gene expression of
GATA1, ZFPM1 (also known as FOG1), FLI1, NFE2, and VWF
in BM CD341 cells (Figure 3B) and imMKCLs (Figure 6C) at
levels higher than rhTPO or eltrombopag. We also noted a unique
effect of TA-316 on the expression of growth factor activity-related
genes in imMKCLs. The expressions of VEGFA and FGF2 genes
were preferentially increased in imMKCLs cultured with TA-316
(Figure 7A). Consistent with data that show TA-316 has superior
activity for the promotion of imMKCL proliferation, VEGFA reportedly
plays an important role in hematopoietic stem cell (HSC) survival.19
Considering that TA-316 stimulates a direct pathway to MKs from
HSCs or iHPCs20,21 as well as the induction of VEGFA, we propose
that TA-316 may promote the self-renewal activity of imMKCLs as
well as HSCs/iHPCs. As shown in Figure 2E and supplemental
Figure 4A, TA-316 exhibited its maximum signal intensity at times
(120 to 240 minutes) later than rhTPO (15 minutes) in terms of
STAT5 activation. The differences in TPO-receptor binding and
dissociation kinetics between rhTPO and TA-316 may provide a key
to understanding why TA-316 more effectively mediates platelet
production (Figure 5C).
Chemically synthesized compounds other than CMAs have
been reported to show positive effects in the production of MKs
and platelets from HSCs/iHPCs ex vivo. MK1, a platelet-derived
growth factor receptor agonist, promotes megakaryopoiesis from
CD341 cells.22 In addition, StemRegenin 1, an antagonist of the
aryl hydrocarbon receptor, increases the number of proplatelet-
producing MKs from CD341 cells by repressing CYP1B1
expression.23 We confirmed that StemRegenin 1 increases the
number of platelets from imMKCLs when cultured with TA-316
(data not shown). Thus, TA-316 could be applied in combination
with other small molecule modulators that function independent of
the TPO/c-MPL signal.
In conclusion, our findings demonstrate that TA-316 enhances the
production of human platelets from imMKCLs and that TA-316 has
the potential to become an indispensable tool for the expansion of
platelets from hiPSCs, in combination with an imMKCL system.
Moreover, TA-316 could help elucidate the roles of factors involved
in biased megakaryopoiesis and thrombopoiesis from HSCs/iHPCs,
such as VWF, VEGFA, and FGF2.
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*p <0.05, **p <0.01, vs. Vehicle
Figure 7. An inhibitor of FGF or VEGF receptors eliminates the superior effect of TA-316 on imMKCL proliferation. imMKCLs cultured with rhTPO (50 ng/mL), TA-316
(200 ng/mL), eltrombopag (1000 ng/mL), or DMSO (0.05%). (A) Cells were collected on day 11 (genes on). mRNA expressions of VEGFA and FGF2 (genes on) were evaluated
using Taqman PCR assays.GAPDH served as an internal control. (B) FGFR antagonist PD173074 (100 nM; WAKO), VEGFR antagonist axitinib (5 nM; Toronto Research Chemicals,
Toronto, Canada), or epithelial growth factor receptor antagonist gefitinib (1 mM, Santa Cruz Biotechnology, Dallas, TX) was added to the imMKCLs, which were cultured with TA-316
(200 ng/mL) for 4 days (genes on). Cell proliferation was assessed based on 0.4% Trypan blue staining (Thermo Fisher Scientific). Data represent the mean and SD; *P, .05, **P, .01.
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